Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.37 |
| ▸ | FEN1 | P39748 | 6/20 | 0.37 |
| ▸ | SGK1 | O00141 | 7/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14633930 | 0.92 | PIK3CA (0.42) | PIK3CAGRM4GSK3AGSK3BALOX5AP | |
| SCHEMBL2470683 | 0.91 | GSK3A (0.39) | PIK3CAGSK3AGSK3BALOX5APFEN1 | |
| SCHEMBL2468125 | 0.86 | PIK3CA (0.39) | PIK3CAGRM4GSK3AGSK3BALOX5AP | |
| SCHEMBL14633953 | 0.81 | SGK1 (0.42) | PIK3CAGRM4SGK1PIK3CDPIK3CB | |
| SCHEMBL14634007 | 0.80 | PIK3CA (0.39) | PIK3CAGSK3AGSK3BALOX5APFEN1 | |
| SCHEMBL14634078 | 0.79 | DHFR (0.34) | PIK3CAGSK3AGSK3BALOX5APFEN1 | |
| SCHEMBL2466560 | 0.78 | PIK3CA (0.39) | PIK3CAGRM4GSK3AGSK3BALOX5AP | |
| SCHEMBL14633983 | 0.74 | ALOX5AP (0.44) | GSK3BALOX5APFEN1SGK1NR1H2 | |
| SCHEMBL14633669 | 0.73 | PIK3CA (0.38) | PIK3CAGSK3AGSK3BALOX5APFEN1 | |
| SCHEMBL14633800 | 0.73 | NR1H2 (0.49) | ALOX5APFEN1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | PIK3CA 78/4885GRM4 4019/4885GSK3A 644/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | PIK3CA 99/4885GRM4 3206/4885GSK3A 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.